Metastatic Colorectal Cancer - Epidemiology Forecast - 2032
Description
DelveInsight's "Metastatic Colorectal Cancer (mCRC)- Epidemiology Forecast-2032" report delivers an in-depth understanding of the mCRC, historical and forecasted epidemiology as well as the mCRC trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2019-2032
Metastatic Colorectal Cancer mCRC Understanding
The DelveInsight’s mCRC epidemiology report gives a thorough understanding of mCRC by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
CRC that spreads, or metastasizes, to the lungs, liver, or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer in the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.
Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one’s children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.
Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.
If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.
Diagnosis
The first and foremost step in evaluating, Patients can present with a wide range of signs and symptoms such as occult or overt rectal bleeding, change in bowel habits, anemia, or abdominal pain. However, CRC is largely an asymptomatic disease until it reaches an advanced stage. By contrast, rectal bleeding is a common symptom of both benign and malignant causes. Therefore additional risk factors might be needed to help identify those people who should undergo further investigation by colonoscopy. New-onset rectal bleeding should generally prompt colonoscopy in individuals aged 45 years or older. In younger patients, additional factors are used to identify those at highest risk for CRC (e.g., having a family history of CRC, change in bowel habits, unexplained weight loss, and blood mixed with the stool as opposed to blood on the surface of the stool).
For diagnosing CRC, colonoscopy is the method of choice. Colonoscopy identification of advanced lesions is relatively straightforward, but early CRCs might appear as very subtle mucosal lesions (e.g., an innocuous flat laterally spreading polyp), imaging, laboratory, pathology, biopsy, blood test, tumor based tests, etc.
Metastatic Colorectal Cancer (mCRC) Epidemiology
The epidemiology section provides insights about the historical and current mCRC patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted mCRC epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total incident cases of mCRC were 241,115 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
The disease epidemiology covered in the report provides historical as well as forecasted mCRC epidemiology [segmented as Total Incident Cases of CRC and Total Incident Cases of mCRC] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Metastatic Colorectal Cancer mCRC Epidemiology
The epidemiology segment also provides the mCRC epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
KOL- Views
To keep up with the current mCRC patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the mCRC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report
The report covers the descriptive overview of mCRC, explaining their causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of mCRC.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by Total Incident cases of CRC and Total incident cases of mCRC.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence mCRC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for mCRC
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Metastatic Colorectal Cancer mCRC Report Key Strengths
11 Years Forecast
7MM Coverage
mCRC Epidemiology Segmentation
Key Questions
Epidemiology Insights:
What are the disease risk, burden, and regional/ethnic differences of mCRC?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical mCRC patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of mCRC in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM concerning the patient population about mCRC?
Out of all 7MM countries, which country would have the highest incident population of mCRC during the forecast period (2019-2032)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the mCRC Disease market
To understand the future market competition in the mCRC Disease market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for mCRC Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for the mCRC Disease market
To understand the future market competition in the mCRC Disease market
Geography Covered
The United States
EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Japan
Study Period: 2019-2032
Metastatic Colorectal Cancer mCRC Understanding
The DelveInsight’s mCRC epidemiology report gives a thorough understanding of mCRC by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. Colorectal cancer (CRC) is the third most common, with metastasis being the major cause of death in the majority of patients. CRC starts in the colon or the rectum. These cancers can also be called colon cancer or rectal cancer, depending on where they start. Colon cancer and rectal cancer are often grouped because they have many features in common. CRC may develop when polyps, mushroom-like growths inside the colon, grow and become cancerous or cells along the lining of the colon or rectum mutate and grow out of control, forming a tumor.
CRC that spreads, or metastasizes, to the lungs, liver, or any other organ is called metastatic colorectal cancer (mCRC). The most common site of metastases for colon or rectal cancer in the liver. CRC cells may also spread to the lungs, bones, brain, or spinal cord. If a person has been treated for CRC and cancer cells have been found in these areas, it may be a sign that the original CRC has spread. mCRC is different from recurrent CRC.
Generally, most CRCs (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one’s children. Inherited CRCs are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of CRC is not known.
Most CRCs start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Some types of polyps can change into cancer over time (usually many years), but not all polyps become cancer. The chance of a polyp turning into cancer depends on the type of polyp it is.
If cancer forms in a polyp, it can grow into the wall of the colon or rectum over time. The wall of the colon and rectum is made up of many layers. CRC starts in the innermost layer (the mucosa) and can grow outward through some or all of the other layers. When cancer cells are in the wall, they can then grow into blood vessels or lymph vessels (tiny channels that carry away waste and fluid). From there, they can travel to nearby lymph nodes or distant parts of the body. The stage (extent of spread) of a CRC depends on how deeply it grows into the wall and if it has spread outside the colon or rectum.
Diagnosis
The first and foremost step in evaluating, Patients can present with a wide range of signs and symptoms such as occult or overt rectal bleeding, change in bowel habits, anemia, or abdominal pain. However, CRC is largely an asymptomatic disease until it reaches an advanced stage. By contrast, rectal bleeding is a common symptom of both benign and malignant causes. Therefore additional risk factors might be needed to help identify those people who should undergo further investigation by colonoscopy. New-onset rectal bleeding should generally prompt colonoscopy in individuals aged 45 years or older. In younger patients, additional factors are used to identify those at highest risk for CRC (e.g., having a family history of CRC, change in bowel habits, unexplained weight loss, and blood mixed with the stool as opposed to blood on the surface of the stool).
For diagnosing CRC, colonoscopy is the method of choice. Colonoscopy identification of advanced lesions is relatively straightforward, but early CRCs might appear as very subtle mucosal lesions (e.g., an innocuous flat laterally spreading polyp), imaging, laboratory, pathology, biopsy, blood test, tumor based tests, etc.
Metastatic Colorectal Cancer (mCRC) Epidemiology
The epidemiology section provides insights about the historical and current mCRC patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides a historical as well as forecasted mCRC epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total incident cases of mCRC were 241,115 cases in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
The disease epidemiology covered in the report provides historical as well as forecasted mCRC epidemiology [segmented as Total Incident Cases of CRC and Total Incident Cases of mCRC] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Metastatic Colorectal Cancer mCRC Epidemiology
The epidemiology segment also provides the mCRC epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
KOL- Views
To keep up with the current mCRC patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the mCRC domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Scope of the Report
The report covers the descriptive overview of mCRC, explaining their causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of mCRC.
The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
The report provides the segmentation of the disease epidemiology for 7MM by Total Incident cases of CRC and Total incident cases of mCRC.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence mCRC R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for mCRC
Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Metastatic Colorectal Cancer mCRC Report Key Strengths
11 Years Forecast
7MM Coverage
mCRC Epidemiology Segmentation
Key Questions
Epidemiology Insights:
What are the disease risk, burden, and regional/ethnic differences of mCRC?
What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What is the historical mCRC patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
What would be the forecasted patient pool of mCRC in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
Where will be the growth opportunities in the 7MM concerning the patient population about mCRC?
Out of all 7MM countries, which country would have the highest incident population of mCRC during the forecast period (2019-2032)?
At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to buy
The report will help in developing business strategies by understanding trends shaping and driving the mCRC Disease market
To understand the future market competition in the mCRC Disease market and Insightful review of the key market drivers and barriers
Organize sales and marketing efforts by identifying the best opportunities for mCRC Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
Organize sales and marketing efforts by identifying the best opportunities for the mCRC Disease market
To understand the future market competition in the mCRC Disease market
Table of Contents
154 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Metastatic Colorectal Cancer (mCRC) Market Overview at a Glance
- 3.1. Market Share (%) Distribution of mCRC in 2019
- 3.2. Market Share (%) Distribution of mCRC in 2032
- 4. Executive Summary of Metastatic Colorectal Cancer (mCRC)
- 4.1. Key Events
- 5. Epidemiology and Market Methodology
- 6. Disease Background and Overview
- 6.1. Introduction
- 6.2. Causes
- 6.3. Symptoms
- 6.4. CRC Staging
- 6.5. Risk Factors of CRC
- 6.6. Molecular Subtypes of CRC
- 6.7. Mechanisms of Metastasis in CRC
- 6.8. Drug Resistance in mCRC
- 6.9. Clinical Presentation of mCRC
- 6.10. Unusual Sites of Metastasis in CRC
- 6.10.1. Uterine Metastasis
- 6.10.2. Penile Metastasis
- 6.10.3. Scrotal Metastasis
- 6.10.4. Prostatic Metastasis
- 6.10.5. Bladder Metastasis
- 6.10.6. Peritoneal Pseudomyxoma
- 6.10.7. Abdominal Wall Metastasis
- 6.10.8. Bone Metastasis
- 6.10.9. Carcinomatous Lymphangitis
- 6.10.10. Adenopathies
- 6.10.11. Pancreatic Metastasis
- 6.11. Biomarkers in mCRC
- 6.11.1. Prognostic Biomarkers
- 6.11.2. Patient-Related Factors
- 6.11.3. Tumor-related Factors
- 6.11.4. Predictive Biomarkers
- 6.11.5. Markers to Predict 5-FU Response and Toxicity
- 6.11.6. Predicting Response to EGFR Therapy
- 6.11.7. Predicting Response to VEGF Inhibitors
- 6.11.8. Technology-Facilitated Biomarkers
- 6.12. Diagnosis
- 6.12.1. Clinical symptoms
- 6.12.2. Endoscopy
- 6.12.3. Imaging
- 6.12.4. Laboratory
- 6.12.5. Pathology
- 6.12.6. Biopsy
- 6.12.7. Molecular Testing of the Tumor
- 6.12.8. Blood Tests
- 6.12.9. Tumor-based Tests
- 6.12.10. Diagnosis of colorectal liver metastasis
- 7. Recognized Establishments
- 8. Treatment of Metastatic Colorectal Cancer (mCRC)
- 8.1. Initial/First-line Treatment of mCRC
- 8.2. Second and Third-line Treatment of mCRC
- 8.3. Therapies using medication
- 8.4. Surgery
- 8.5. Adjuvant therapy
- 8.6. Follow-up
- 8.7. Palliation
- 8.8. Maintenance Therapy
- 8.9. Treatment of Colon Cancer That Has Metastasized to a Single Site
- 9. Treatment of Patients with Late-stage Colorectal Cancer: ASCO Resource-Stratified Guideline (2020)
- 10. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer (2016)
- 10.1. Recommendations
- 10.1.1. Recommendation 1: Tissue handling
- 10.1.2. Recommendation 2: A selection of specimens for biomarker testing
- 10.1.3. Recommendation 3: Tissue selection
- 10.1.4. Recommendation 4: RAS testing
- 10.1.5. Recommendation 5: BRAF testing
- 10.1.6. Recommendation 6: MSI testing
- 10.1.7. Recommendation 7: Biomarkers of chemotherapy sensitivity and toxicity
- 10.1.8. Recommendation 8: Emerging biomarkers not recommended for routine patient management outside of a clinical trial setting
- 10.1.9. Recommendation 9: Emerging technologies
- 10.1.10. Recommendation 10: OMD
- 10.1.11. Recommendation 11: Imaging in the identification and management of disease
- 10.1.12. Recommendation 12: Perioperative treatment
- 10.1.13. Recommendation 13: Conversion therapy
- 10.1.14. Recommendation 14: Ablative techniques
- 10.1.15. Recommendation 15: Local ablation techniques
- 10.1.16. Recommendation 16: Embolization
- 10.1.17. Recommendation 17: Cytoreductive surgery and HIPEC
- 10.1.18. Recommendation 18: First-line systemic therapy combinations according to the targeted agent used
- 10.1.19. Recommendation 19: Maintenance therapy
- 10.1.20. Recommendation 20: Second-line combinations with targeted agents
- 10.1.21. Recommendation 21: Third-line therapy
- 10.2. Consensus recommendations on the use of cytotoxics and biologicals in the first- and subsequent-line treatment of patients with mCRC
- 10.2.1. Consensus recommendation for patients where cytoreduction with 'conversion' and/or the integration of local ablative treatment is the goal
- 10.2.2. Consensus recommendation for patients where cytoreduction is needed because of aggressive biology and/or risk of developing or existing severe symptoms
- 10.2.3. Consensus recommendation for patients where disease control is the goal
- 11. National Institute for Health and Care Excellence (NICE) Guidelines: Colorectal Cancer (2020)
- 11.1. Management of metastatic disease
- 11.1.1. People with asymptomatic primary tumor
- 11.1.2. People with mCRC in the liver
- 11.1.3. People with metastatic colorectal cancer in the lung
- 11.1.4. People with metastatic colorectal cancer in the peritoneum
- 11.2. Ongoing care and support
- 11.2.1. Follow-up for detection of local recurrence and distant metastases
- 12. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM) (2016)
- 12.1. Metastatic CRC Treatment Recommendations
- 12.1.1. Evaluation of elderly patients
- 12.1.2. Surgery for advanced disease
- 12.1.3. Locoregional treatments
- 13. Treatment guidelines of metastatic colorectal cancer in older patients from the French Society of Geriatric Oncology (SoFOG)
- 13.1. Recommendations on palliative chemotherapy indication for older patients with mCRC
- 13.2. Recommendations for cytotoxic chemotherapy in older patients:
- 13.3. Anti-angiogenic recommendations for older:
- 13.4. Recommendations for anti-EGFR, regorafenib and trifluridinetipiracil in older patients:
- 14. Spanish Society of Medical Oncology (SEOM) clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018)
- 15. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines for the treatment of colorectal cancer- 2019
- 15.1. Treatment strategies for Stage IV CRC
- 15.2. Treatment strategies for hematogenous metastases
- 15.2.1. Treatment strategies for liver metastases
- 15.2.2. Treatment strategies for brain metastases
- 15.2.3. Treatment strategies for hematogenous metastases to other organs
- 16. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Colon and Rectal Cancer (2021)
- 17. Epidemiology and Patient Population
- 17.1. Key Findings
- 17.2. Epidemiology of Metastatic Colorectal Cancer (mCRC)
- 17.3. Epidemiology Scenario
- 17.3.1. Total Incident Cases of Colorectal Cancer (CRC)
- 17.3.2. Total Incident Cases of Metastatic Colorectal Cancer (mCRC)
- 18. Appendix
- 18.1. Bibliography
- 18.2. Report Methodology
- 19. DelveInsight Capabilities
- 20. Disclaimer
- 21. About DelveInsight
- Table 1: Summary of Metastatic Colorectal Cancer, Market, Epidemiology, and Key Events (2019-2032)
- Table 2: AJCC Staging for CRC
- Table 3: Prognostic factors in mCRC
- Table 4: Predictive factors for targeted therapies in mCRC.
- Table 5: The list of biomarkers used in the clinical practice of mCRC
- Table 6: Recognized Establishments
- Table 7: Percentage of patients that are prescribed different lines of treatment for mCRC.
- Table 8: Recommendations on Diagnosis .
- Table 9: Recommendations on Staging .
- Table 10: First-Line Treatment
- Table 11: Recommendations on Second-Line Systemic Colorectal Metastatic Treatment .
- Table 12: Recommendations on Third-Line and Fourth-Line Systemic Colorectal Metastatic Treatment .
- Table 13: Recommendations on Liver-Directed Therapies in Patients with mCRC .
- Table 14: Summary Treatment Options for Late-Stage CRC .
- Table 15: Recommendations on Surveillance/Follow-up .
- Table 16: mCRC: SIGN recommendations
- Table 17: mCRC treatment: GRADE recommendations
- Table 18: Evaluation of elderly patients: SIGN recommendations
- Table 19: Surgery: SIGN recommendations
- Table 20: Liver-directed therapies: SIGN recommendations
- Table 21: Non-liver-directed therapies: SIGN recommendations
- Table 22: Recommendations for diagnosis and treatment of mCRC.
- Table 23: Total Incident Cases of Metastatic Colorectal Cancer (CRC) in the 7MM (2019-2032)
- Table 24: Total Incident Cases of Metastatic Colorectal Cancer (mCRC) in the 7MM (2019-2032)
- Figure 1: Epidemiology and Market Methodology
- Figure 2: Mechanisms of metastasis in CRC- hematogenous versus peritoneal spread
- Figure 3: Current and emerging biomarkers used in personalizing treatment for patients with mCRC.
- Figure 4: EGFR signaling pathway with potential predictive markers.
- Figure 5: VEGF signaling pathway.
- Figure 6: NCCN Guidelines for Colon Cancer.
- Figure 7: NCCN Guidelines for the treatment of Rectal Cancer
- Figure 8: Total Incident Cases of CRC in the 7MM (2019-2032)
- Figure 9: Total Incident Cases of mCRC in the 7MM (2019-2032)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.